Allos Therapeutics Announces Proposed Public Offering of Common Stock

WESTMINSTER, Colo.--(Business Wire)--
Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that it is offering to
sell, subject to market and other conditions, 11,000,000 primary shares of its
common stock pursuant to an effective shelf registration statement in an
underwritten public offering. Allos Therapeutics also intends to grant the
underwriters a 30-day option to purchase up to an aggregate of 1,650,000
additional primary shares of common stock to cover over-allotments, if any. All
of the shares in the offering are to be sold by Allos Therapeutics, with
proceeds to be used to support the commercialization of FOLOTYN (pralatrexate
injection), preclinical research and clinical development of FOLOTYN, and
general corporate purposes. J.P. Morgan Securities Inc. and Citigroup Global
Markets, Inc. are acting as joint book-running managers of the proposed
offering. Leerink Swann LLC is acting as co-lead manager of the offering. JMP
Securities LLC is acting as co-manager of the offering.

A shelf registration statement relating to the shares was filed with the
Securities and Exchange Commission and is effective. Information about the
offering is available in the preliminary prospectus supplement to be filed with
the Securities and Exchange Commission. This press release does not constitute
an offer to sell, or the solicitation of an offer to buy, these securities, nor
will there be any sale of these securities in any state or other jurisdiction in
which such offer, solicitation or sale is not permitted. Any offer, if at all,
will be made only by means of a prospectus, including a prospectus supplement,
forming part of the effective shelf registration statement.

Copies of the preliminary prospectus supplement and accompanying prospectus may
be obtained by contacting J.P. Morgan Securities Inc., Attention: Prospectus
Department, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245 or by calling
(718) 242-8002 or Citigroup Global Markets, Inc., Prospectus Department,
Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, NY 11220, (800)
831-9146.

About Allos Therapeutics

Allos Therapeutics, Inc. (Nasdaq: ALTH) is a biopharmaceutical company committed
to the development and commercialization of innovative anti-cancer therapeutics.

Safe Harbor Statement

This press release contains forward-looking statements that are made pursuant to
the safe harbor provisions of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include statements concerning the
completion, timing and size of the proposed financing and other statements which
are other than statements of historical facts. In some cases, you can identify
forward-looking statements by terminology such as "may," "will," "should,"
"expects," "intends," "plans," anticipates," "believes," "estimates,"
"predicts," "projects," "potential," "continue," and other similar terminology
or the negative of these terms, but their absence does not mean that a
particular statement is not forward-looking. Such forward-looking statements are
not guarantees of future performance and are subject to risks and uncertainties
that may cause actual results to differ materially from those anticipated by the
forward-looking statements. These risks and uncertainties include, among others:
the risk that the financing may be delayed or may not occur due to market or
other conditions and the satisfaction of customary closing conditions related to
the proposed public offering. Additional information concerning these and other
factors that may cause actual results to differ materially from those
anticipated in the forward-looking statements is contained in the "Risk Factors"
section of the Company's Quarterly Report on Form 10-Q for the quarter ended
June 30, 2009, and in the Company's other periodic reports and filings with the
Securities and Exchange Commission and the prospectus supplement related to the
offering. The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All forward-looking
statements are based on information currently available to the Company on the
date hereof, and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after the date of
this presentation, except as required by law.

Note: The Allos logo and FOLOTYN name are trademarks of Allos Therapeutics,
Inc.

Allos Therapeutics, Inc.
Monique Greer, 720-540-5268
mgreer@allos.com

Copyright Business Wire 2009